key: cord-0976342-ag5be7r6
authors: Pacl, Hayden T.; Tipper, Jennifer L.; Sevalkar, Ritesh R.; Crouse, Andrew; Crowder, Camerron; Holder, Gillian D.; Kuhlman, Charles J.; Chinta, Krishna C.; Nadeem, Sajid; Green, Todd J.; Petit, Chad M.; Steyn, Adrie J.C.; Might, Matthew; Harrod, Kevin S.
title: Water-soluble tocopherol derivatives inhibit SARS-CoV-2 RNA-dependent RNA polymerase
date: 2021-07-14
journal: bioRxiv
DOI: 10.1101/2021.07.13.449251
sha: e8c5bf2f95c675ce5656772091579f1cc3ecc02d
doc_id: 976342
cord_uid: ag5be7r6

The recent emergence of a novel coronavirus, SARS-CoV-2, has led to the global pandemic of the severe disease COVID-19 in humans. While efforts to quickly identify effective antiviral therapies have focused largely on repurposing existing drugs1–4, the current standard of care, remdesivir, remains the only authorized antiviral intervention of COVID-19 and provides only modest clinical benefits5. Here we show that water-soluble derivatives of α-tocopherol have potent antiviral activity and synergize with remdesivir as inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). Through an artificial-intelligence-driven in silico screen and in vitro viral inhibition assay, we identified D-α-tocopherol polyethylene glycol succinate (TPGS) as an effective antiviral against SARS-CoV-2 and β-coronaviruses more broadly that also displays strong synergy with remdesivir. We subsequently determined that TPGS and other water-soluble derivatives of α-tocopherol inhibit the transcriptional activity of purified SARS-CoV-2 RdRp and identified affinity binding sites for these compounds within a conserved, hydrophobic interface between SARS-CoV-2 nonstructural protein 7 and nonstructural protein 8 that is functionally implicated in the assembly of the SARS-CoV-2 RdRp6. In summary, we conclude that solubilizing modifications to α-tocopherol allow it to interact with the SARS-CoV-2 RdRp, making it an effective antiviral molecule alone and even more so in combination with remdesivir. These findings are significant given that many tocopherol derivatives, including TPGS, are considered safe for humans, orally bioavailable, and dramatically enhance the activity of the only approved antiviral for SARS-CoV-2 infection7–9.

The emergence of multiple coronaviruses (CoVs) into the human population in recent years [10] [11] [12] highlights the need for the rapid development of broad-spectrum interventional strategies against genetically distinct CoVs. Despite the unprecedented rapid development of effective vaccines targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, breakthrough infections in the immunocompromised 13-19 , infections in the young and elderly lacking a full repertoire of immunological responses 20 , vaccine reticence or hesitancy 21 , and the inequitable distribution of vaccines globally 22 indicate that therapeutic interventions will be required to limit severe disease and substantial mortality associated with pandemic SARS-CoV-2 infection. Currently, remdesivir, under emergency FDA authorization, is the only antiviral to show improvement of clinical outcomes, albeit with limited effectiveness and the limitation of intravenous administration 5 . Furthermore, breakthrough infections and viral evolution of resistant strains is possible 14, 23 . This highlights the need for identifying new antivirals with broad efficacy against CoVs, and the potential for combinatorial interventional antivirals that reduce the development of resistance. Here, we employed a novel artificial intelligence query of FDA-approved compounds for repurposing as antivirals against SARS-CoV-2 and identify tocopherol derivatives with potent antiviral activity and synergy with remdesivir.

To select candidates for in vitro screening, we employed the open-source artificial intelligence software mediKanren to perform a logical query of the existing literature for compounds that are known to induce or inhibit host proteins involved in reducing or enhancing viral replication, respectively (https://github.com/webyrd/mediKanren) ( Fig  S1) .

Complemented by a manual review of the available literature, we identified over 1300 compounds with proposed antiviral activity, of which nearly 100 were prioritized for in vitro screening (Table   S1 ). To assess the antiviral activity of these compounds against virulent SARS-CoV-2, we adapted a traditional focus-forming assay in BSL-3 biocontainment by allowing foci to expand gradually over 48 hours, using progression of viral staining as a proxy for the magnitude of infection ( Figure S2 ). Employing this method, we identified 12 compounds capable of reducing SARS-CoV-2 propagation by more than 90% at a concentration of 10 µM ( Figure 1A ). Follow-up testing revealed these compounds exhibit reliable dose-response relationships within our antiviral assay that are independent of their toxicity profile ( Figure 1B) .

We expanded the characterization of candidate antiviral compounds by evaluation of antiviral activity across a range of conditions. We found that five of our top 12 compounds reduced the burden of SARS-CoV-2 in infected Calu3 cells, a human lung epithelial cell line, by greater than 90% ( Figure 1C ). Interestingly, four of these five drugs-niclosamide, remdesivir, lopinavir, and D-α-tocopherol polyethylene glycol succinate (TPGS)-were the only drugs to show maximum efficacy in halting an established SARS-CoV-2 infection in VeroE6 cells ( Figure 1D ).

On the other hand, each of the top compounds except E-64d demonstrated strong antiviral activity against the seasonal β-coronavirus, OC43 ( Figure 1E ; Figure S3 ), suggesting that the majority of the compounds we identified are effective against β-coronaviruses more broadly. Overall, these findings describe four compounds with robust, broad-spectrum antiviral activity and therapeutic applications.

Given the threat of drug-resistance evolving in response to single-agent therapy, as well as the modest effects and limited supply of currently available antivirals for the treatment of COVID-19, we screened our top compounds for synergistic combinations. Relying on the principle of Loewe Additivity 24,25 , we combined our top compounds in a pairwise fashion to yield equipotent mixtures with a predicted efficacy of 50%. While the myriad combinations revealed mostly additive effects, the combination of remdesivir and TPGS resulted in an 8-fold increase in potency ( Figure   2A ). Follow-up testing of equipotent combinations of the top drugs with either remdesivir ( Figure   2B ; Figure S4 ) or TPGS ( Figure 2C ) revealed that this combination was indeed unique and doseresponsive across a range of concentrations. To fully characterize the synergy between TPGS and remdesivir we expanded our analysis across a range of mixtures to perform response-surface analysis, an extension of traditional isobologram analysis 25 . We identified that an equipotent mixture of TPGS and remdesivir was optimal for antiviral activity ( Figure 2D, E) , and, at this ratio, we observed a reduction of approximately 10-fold in the IC 90 ( Figure 2E ). Of note, including one drug as at least 10% of the total combined dose dramatically enhances the potency of the other, suggesting that synergism can be honed to limiting availability to either compound.

Given the pronounced synergy between remdesivir and TPGS, we next sought to understand the mechanism for the antiviral activity of TPGS, starting with its known, biologically- of PGP and antiviral activity ( Figure S5A ). Additionally, we further screened well-characterized inhibitors and inducers of PGP for antiviral activity against SARS-CoV-2 ( Figure S5B -G). While the majority showed no effect, amiodarone, another non-competitive inhibitor of PGP, exhibited antiviral activity against SARS-CoV-2 ( Figure S5G ). Amiodarone, however, showed no ability to synergize with remdesivir ( Figure S4H ), suggesting that the antiviral activities of TPGS and amiodarone are mediated by independent mechanisms and are therefore unlikely to be related to their commonality as PGP inhibitors. Additionally, TPGS is a surfactant. Other surfactant molecules with related chemical structures showed no antiviral activity ( Figure S5I -L).

Finally, we tested the constituent components of TPGS: D-α-tocopherol, succinate, and polyethylene glycol with a molecular weight of 1000 Da (PEG-1000; Figure S6A ). α-tocopherol alone is insoluble in an aqueous environment, so we instead tested α-tocopherol succinate (αTOS) and α-tocopherol phosphate (αTOP). While we observed no effect from αTOP, PEG-1000, or succinate alone ( Figure S6B -D), we found that αTOS is capable of inhibiting SARS-CoV-S5E). These findings suggests that α-tocopherol is the active component of TPGS, and succinate and PEG-1000 contribute indirectly to its potency.

To determine whether the synergy with remdesivir and the increased potency of TPGS was specific to PEG-1000 or limited to the D-isomer of α-tocopherol, we tested a related Figure S6F ) as well as the ability to synergize with remdesivir ( Figure S6G ,H). Within logical constraints, these data suggest that medicinal chemistry targeting the size of the PEG or the isomer of the α-tocopherol may be modified to yield a compound with different physical and chemical properties that retains its antiviral activity.

We next sought to determine where in the process of viral propagation TPGS acts. We therefore infected VeroE6 cells with SARS-CoV-2 for 30 minutes and measured both intracellular and extracellular SARS-CoV-2 genome expression at 0, 3, and 9 hours post infection (hpi). We observed no decrease in viral attachment or uptake, but we detected a ~4000-fold reduction in genomic material at 9 hpi in cells treated by either remdesivir or TPGS ( Figure 3A) . Notably, there was no detectable extracellular genome at any of these timepoints, indicating inhibition of viral transcriptional activity alone (data not shown).

We expanded our analysis of the expression of SARS-CoV-2 RNA by sequencing mRNA from the samples in our time course experiment and analyzing the transcriptome of infected host cells. We observed the same profound reduction in transcripts mapped to each of the genes in the SARS-CoV-2 genome and detected no RNA corresponding to many of the viral genes in our treated samples ( Figure S7A ). The latter point, in particular, suggests that TPGS inhibits the transcription of viral genes. With regard to the transcription of host mRNA, principle component analysis revealed treated and untreated samples at 9 hpi have distinct transcriptomes ( Figure   S7B ). Follow up gene ontology analysis of TPGS-treated and untreated cells at 9 hpi revealed that of the top 20 biological processes identified as enriched, ten were related to lipid metabolism ( Figure S7C ). The latter suggests that TPGS-treated cells respond to the tocopherol component of TPGS.

Considering the potent synergy between TPGS and remdesivir, a known inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) 28, 29 , as well as the results from our time course experiment, we hypothesized that TPGS inhibits the SARS-CoV-2 RdRp. To directly test our hypothesis, we measured the ability of TPGS to inhibit the transcriptional activity of purified SARS-CoV-2 RdRp composed of the catalytic subunit NSP12, and two accessory proteins, NSP7

and NSP8. Indeed, TPGS is a potent inhibitor of the transcriptional activity of the SARS-CoV-2

RdRp (IC 50 = 212 nM; Figure 3B )-approximately 100-fold more potent than the active metabolite of remdesivir (RTP; IC 50 = 26 µM; Figure 3B ).

Interestingly, we also observed that TPGS does not inhibit RdRp at concentrations above its critical micelle concentration (CMC; Figure 3C ) 30 . This led us to the expanded hypothesis that water-soluble derivatives of α-tocopherol inhibit the SARS-CoV-2 RdRp. We tested this hypothesis using αTOS and αTOP in our RdRp transcriptional assay. Consistent with our results in VeroE6 cells, αTOS was capable of inhibiting transcription; however, we also observed comparable inhibition of the SARS-CoV-2 RdRp by αTOP ( Figure 3D ). These findings suggests that while the efficacy of these compounds as antivirals may vary in the more complex cellular environment, water-soluble tocopherols inhibit the SARS-CoV-2 RdRp.

Finally, to further elucidate the interaction between water-soluble tocopherols and the SARS-CoV-2 RdRp, a series of computational docking studies were performed. Due to the challenge of modeling the flexibility of the PEG in the TPGS molecule as well as the ability of αTOS to inhibit the purified RdRp as well as viral replication in cells, we performed these studies for αTOS. Our docking studies across the individual components of the RdRp identified high affinity binding sites for αTOS within each NSP7, NSP8, and NSP12 ( Figure 3E ,F; Figure S8 ).

Interestingly, while the top poses for αTOS were spread to a few locations across the surface of NSP12, our docking studies on the interaction of αTOS with NSP7 and NSP8 each converged to a single region ( Figure S8A -C). In each case, the most energetically favorable binding poses localized with residues that participate in one of the two recently described hydrophobic interfaces that is required for the assembly of the functional RdRp ( Figure 3G ; Figure S8D ) 6 . The residues within this interface are highly conserved across coronaviruses, and site directed mutagenesis of several residues within this interface reduced or ablated the transcriptional activity of the SARS-CoV-2 RdRp 6 . Taken together, these findings strongly support a mechanism by which TPGS prevents or destabilizes the assembly of the SARS-CoV-2 RdRp.

Since TPGS is an inhibitor of the SARS-CoV-2 RdRp, we next hypothesized that the synergy of TPGS and remdesivir stems from independent mechanisms of inhibition of transcriptional activity. We combined TPGS and RTP at concentrations that independently led to intermediate inhibition of transcription in our RdRp assay and determined the combination index of these mixtures. Contrary to our hypothesis, we observed a purely additive combinatorial effect ( Figure 4A ). This suggests that the synergy between these compounds stems from a mechanism beyond the inhibition of transcription alone.

Given these results and the recent description of remdesivir as an inhibitor of the guanylyl transferase (GTase) activity of NSP12 31 , we next decided to test GTase activity of NSP12 in the presence of TPGS. Compared to untreated, TPGS enhanced the GTase activity of the NSP12 in vitro ( Figure 4B ,C). This suggests that in the presence of TPGS, the RdRp function of NSP12 is inhibited, though the alternate GTase function of NSP12 is not. However, in the presence of both TPGS and remdesivir, both known activities of NSP12-essential for the production of mature viral RNA-are potently inhibited ( Figure 4D ). Blocking both distinct enzymatic functions could yield the observed synergy.

Here, we have identified water-soluble derivatives of tocopherol as inhibitors of the SARS-CoV-2 RdRp. Importantly, the most potent of these tested, TPGS, synergizes with remdesivir to yield a highly effective combination therapy. Docking studies suggest that tocopherol derivatives destabilize or inhibit the assembly of the SARS-CoV-2 RdRp by binding to hydrophobic residues at a highly conserved interface between NSP7 and NSP8 required for the assembly of the functional RdRp formed by NSP12, NSP7, and NSP8 6 .

While there are sites on the surface of NSP12 with marginally higher affinity for αTOSmost notably at the hydrophobic interface between NSP8 and NSP12-( Figure S8E ), all top poses for the models of αTOS interacting with NSP7 and NSP8 localize to a single site within each protein, providing greater confidence in their relevance. This mechanism is further supported by the knowledge that these two sites together form a single interface required for the assembly of the functional SARS-CoV-2 RdRp 6 . Interestingly, this mechanism would explain our observation that TPGS treatment enhances the GTase activity of NSP12 in the presence of NSP7 and NSP8, as the disruption of the assembled RdRp complex in this assay would prevent NSP12 from participating in the assembled RdRp, thereby freeing all NSP12 to participate in 5' capping.

We consider water-solubility a key factor in the potency of these compounds. Regardless of the mechanism, inhibition of the polymerase complex would require the tocopherol molecules to exist in a soluble form within the aqueous environment of the cell. Pegylation is a known method of solubilizing small molecules, and we attribute the considerable improvement in potency to PEG derivatization in TPGS when compared to αTOS. A corollary of this argument is that the antiviral activity of these compounds in a biological context relies on the stability of the solubilizing modification to the tocopherol which varies in biological systems 32 . Should the modification be hydrolyzed, the hydrophobic tocopherol will not remain in solution and will lose its antiviral effect.

This may account for the variable efficacy of antiviral activity between αTOS and αTOP in viral replication assays ( Figure S6D ,E), despite comparable efficacy and potency in our transcriptional activity assay ( Figure 3D ). It is likely that both stability in an aqueous environment and hydrophobicity leading to greater cellular uptake both contribute to the antiviral activity of tocopherol derivatives tested here.

These considerations along with a vast literature highlight the potential of this group of molecules for optimization as clinical therapeutics. TPGS micelles have been studied extensively as a tool to enhance the solubility, oral-bioavailability, and the tissue penetration of numerous drugs 9,33-36 . The critical micelle concentration of TPGS, as well as its capacity for PGP inhibition, can be shifted by modifying the length of the attached PEG molecule 37, 38 . The biological activity of Vitamin E is affected by its stereochemistry [39] [40] [41] , while its antiviral activity is not ( Figure S6F ).

Finally, further solubilizing modifications should be explored to optimize solubility, potency, and stability, as well as the exploration of related tocopherols and isoprenoids. In combination or isolation, these characteristics can be modified to maximize antiviral efficacy while limiting potential host-directed effects of this direct-acting antiviral compound.

Though remdesivir is known to be a non-obligate terminator of transcription effective against SARS-CoV-2 and other viruses 28, 29, 42 , this activity alone does not account for the observed synergy-and therefore complete antiviral activity-observed when in combination with TPGS ( Figure 4A ). We note that remdesivir was recently described as an inhibitor of the GTase activity of NSP12 31 . TPGS does not inhibit this reaction; rather, the GTase activity of NSP12 is shown to be potentiated by TPGS ( Figure 4B,C) . We propose a model where TPGS and remdesivir synergize by inhibiting two sequential enzymatic reactions in the SARS-CoV-2 transcription cycle:

polynucleotide synthesis and mRNA-capping, both of which are essential for cap-dependent translation in mammalian cells 43 . Presumably, both compounds also inhibit the two-step process of viral genomic replication, (+) and (-) strand synthesis of the coronavirus genome. Taken together, it is conceivable that this forms the conceptual framework for TPGS and remdesivir synergy. This model also provides an explanation for the consistent observation that the IC 50 for the antiviral activity of remdesivir is orders of magnitude lower than the IC 50 for the inhibition of the transcriptional or capping activity 2,28,44-46 . It follows, then, that the potency of remdesivir as an antiviral against SARS-CoV-2 may stem from its combined activity against both processes which can be enhanced by more potent transcriptional inhibition from TPGS.

In summary, we have identified a stable, safe, and orally-bioavailable compound, TPGS, that synergizes with the current standard of care, remdesivir, to inhibit SARS-CoV-2 replication.

These findings also argue that inhibition of the GTase activity of NSP12 is an important part of the antiviral activity of remdesivir. Lastly, the antiviral activity of TPGS extends to a larger class of bioactive molecules with unique biophysical characteristics that retain their antiviral activity with chemical modification, opening the door to a new class of antiviral drugs.

Stocks of low-passage VeroE6 (ATCC # C1008) and Calu3 (ATCC # HTB-55) cells were stored in liquid nitrogen. As needed, stocks were revived and grown to confluency in a tissueculture-treated flask at 37°C and 5% CO 2 

Information regarding the drugs used in screening experiments is available in Table S1 .

Where possible, drugs were prepared in 100% DMSO at a concentration of 20 mM, aliquoted to minimize freeze/thaw cycles, and stored at -20°C. If they were insoluble in DMSO, drugs were prepared in tissue culture grade water (Cytiva/Hyclone # SH30529.03). Drugs used in screening experiments were purchased from Millipore Sigma. PGP inhibitors and inducers in Figure S4 were purchased from Cayman Chemicals. Surfactants in Figure S4 were purchased from Millipore Sigma. The active metabolite of remdesivir, GS-443902, was purchased from Med Chem Express and stored at -80°C for a maximum of one month.

The artificial intelligence tool mediKanren was used to efficiently identify FDA-approved, readily available drug compounds hypothesized to target human and/or viral proteins essential for SARS-CoV-2 infection for further screening in vitro ( Figure S1 ). MediKanren is a biomedical reasoning system composed of a custom knowledge-graph database and a constraint- OC43, an identical procedure was followed, except that the primary antibody for viral detection was a monoclonal antibody against the coronavirus group antigen (Milipore Sigma #MAB9013) and the secondary was a horseradish-peroxidase-conjugated goat-anti-mouse antibody (enQuire BioReagents # Q2AB1).

Brightfield images of whole wells were acquired using either the Cytation 5 Cell Imaging

Multi-Mode Reader (BioTek) or the Lionheart FX Automated Microscope (BioTek). Both instruments were operated with Gen5 software (BioTek), and images were acquired with the lowest power objective available-4x for the Cytation 5 and 1.25x for the Lionheart FX, respectively. Focusing was performed with the dual-peak (brightfield) method and stitching of images within a well was performed using the linear-blend method. Whole-well images were then processed in FIJI software 48 where they underwent automated well-detection by thresholding and particle analysis followed by gaussian filtering, background flattening, and thresholding of the original image to determine the proportion of the well stained for viral protein.

The percentage of area determined to be positive for viral protein within each well was normalized to the mean value calculated across all control wells within a given experiment. This resulted in a standardized measurement of "viral burden"-a near-normally distributed variable with a high degree of concordance between replicates and experiments ( Figure S2 ).

Uninfected VeroE6 cells were otherwise treated under the indicated condition as where corresponds to the steepness of the curve, is the lower asymptote of the curve, is the upper asymptote of the curve, and indicates the dose yielding a 50% effect. Because we operationally defined the untreated well as 100% viral burden and we modeled dose-response relationships only for drugs capable of suppressing viral burden to our limit of detection, and were fixed at 0 and 100, respectively, unless otherwise indicated. Gene Ontology analysis was performed with the "goseq" package as previously described 54 .

The framework of Loewe additivity was applied for all assessments of synergy 24 . In brief, Loewe additivity relies on the dose equivalence principle-the dose of drug A that yields a given effect is equivalent to the dose of drug B that yields the same effect-and the principle of sham additivity-a drug added to itself is a purely additive effect 25 . Using the dose-response model for each drug ( Figure 1B) , we calculated the dose of the combined drugs in terms of IC50 equivalents as shown in equation 2 55 :

where is the concentration of drug A that yields effect , is the IC 50 for drug A, is the concentration of drug B that yields effect , and is the IC 50 for drug B. For curve shift analysis, a similar approach to that described for synergy screening was used. In brief, drugs prepared at a concentration of 4 IC 50 equivalents were combined 1:1 with another drug, resulting in an equipotent mixture of two drugs with a total dose of 4 IC50 equivalents. The resulting mixture was then serially diluted to yield a range of concentrations above and below the predicted IC 50 .

For isobologram and response surface analysis, the approach to curve shift analysis was expanded to encompass a range of potency ratios, also known as a fixed-ratio or "ray" design, as shown in equation 3 57 :

3) 1

where was increased from 0 to 1 by 0. 59 .

Following alignment, HTSeq-count (version 0.13.5) was used to count the number of reads mapping to each gene (parameters used: -m union -r pos -t exon -i gene_id -a 10 -s no -f bam) 60 .

The transcriptional activity of the SARS-CoV-2 RdRp was assessed using the SARS-CoV-2 RNA-dependent RNA polymerase kit plus (Profoldin #S2RPA100KE), according to the kit instructions for reactions in a 384-well plate. In brief, reactions were carried out at 35°C for 2 hours in a total of 25 µL in the presence of the indicated treatment condition. 65 µL of fluorescent dye were added and fluorescence was determined on a per-well basis in a Synergy H1 multimode plate reader (BioTek). 0% transcriptional activity was defined by the no-enzyme control and 100% activity was defined by an untreated control.

Docking experiments were performed using Autodock Vina 61 . Individual NSP7 and NSP8 structures were isolated from the structure of the SARS-CoV-2 NSP7-NSP8 complex (PDB ID:

7JLT) 6 while SARS-CoV-2 NSP12 was isolated from the SARS-CoV-2 RNA-dependent RNA polymerase structure (PDB ID: 6M71) 62 

The GTase activity assay was performed as previously described 45 

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Remdesivir for the Treatment of Covid-19 -Final Report

Two conserved oligomer interfaces of NSP7 and NSP8 underpin the dynamic assembly of SARS-CoV-2 RdRP

Treatment of vitamin E deficiency during chronic childhood cholestasis with oral d-α-tocopheryl polyethylene glycol-1000 succinate

Multicenter trial of d-α-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis

Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo

Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

A Novel Coronavirus from Patients with Pneumonia in China

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

SARS-CoV-2 evolution during treatment of chronic infection

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science (80-)

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

Missing the Point -How Primary Care Can Overcome Covid-19 Vaccine "Hesitancy

Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights

SARS-CoV-2 evolution and vaccines: cause for concern?

Analysis of drug combinations: current methodological landscape

Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)

Vitamin e TPGS Pglycoprotein inhibition mechanism: Influence on conformational flexibility, intracellular ATP levels, and role of time and site of access

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science (80-)

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Structural and Spectroscopic Characterization of TPGS Micelles: Disruptive Role of Cyclodextrins and Kinetic Pathways

Identification of guanylyltransferase activity in the SARS-CoV-2 RNA polymerase

All-rac-α-tocopherol acetate is a better vitamin E source than all-rac-α-tocopherol succinate for broilers

Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability

Physicochemical characterization of solid dispersion of furosemide with TPGS

Enhancement of cyclosporin A solubility by dalphatocopheryl-polyethylene-glycol-1000 succinate (TPGS)

Recent advances in the application of vitamin E TPGS for drug delivery

Investigation of the micellar properties of the tocopheryl polyethylene glycol succinate surfactants TPGS 400 and TPGS 1000 by steady state fluorometry

Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers

Affinity for A-Tocopherol Transfer Protein as a Determinant of the

Vitamin E: function and metabolism

Determinants of plasma vitamin E concentrations

Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir

Viral and Cellular mRNA Translation in

Advances in Virus Research

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Identification of guanylyltransferase activity in the SARS-CoV-2 RNA polymerase

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

The Reasoned Schemer

Fiji: an open-source platform for biological-image analysis

R: A language and environment for statistical computing

RStudio: Integrated Development for R

Welcome to the Tidyverse

Interactive web-based data visualization with R, plotly, and shiny

Dose-Response Analysis Using R

Gene ontology analysis for RNA-seq: accounting for selection bias

Comparison of methods for evaluating drug-drug interaction

The search for synergy: a critical review from a response surface perspective

Design and Analysis of Drug Combination Experiments

Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles

Ultrafast universal RNA-seq aligner

HTSeq-A Python framework to work with high-throughput sequencing data

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science (80-)

A graph depicting rank-ordered antiviral activity against SARS-CoV-2 at 10 µM for all drugs tested. Points represent the mean value from two independent experiments. B) Dose response curves for antiviral activity (blue) and viability (red) in VeroE6 cells. The shaded region around each curve represents the 95% confidence interval, while dots represent technical replicates pooled from two independent experiments. C-E) Antiviral activity of the top drugs at 10 µM in C) SARS-CoV-2-infected Calu3 cells, D) SARS-CoV-2-infected VeroE6 cells treated from 24 hpi until 48 hpi, and E) OC43-infected VeroE6 cells. Dots represent technical replicates from one experiment, bars and error bars represent the mean plus or minus the standard error of the mean. All experiments performed at least twice. Shaded regions surrounding each curve represent the 95% confidence interval for the doseresponse model. D) Representative whole-well images captured for E) response-surface analysis of combinations of remdesivir and TPGS. The white, dashed line represents the predicted isobole for the IC 90 while the inset magnifies the origin of the graph. Two technical replicates were used to determine the antiviral activity at each point assayed. All experiments were performed at least twice.

Graph representing the fold change of SARS-CoV-2 genome in infected VeroE6 cells relative to initial uptake in the untreated control. Remdesivir and TPGS were given at a fully effective dose, 10 µM and 30 µM, respectively. Points and error bars represent the mean +/-SEM calculated from two technical replicates. B) Dose-response curves for the transcriptional activity of the SARS-CoV-2 replication complex treated with TPGS (blue) and remdesivir (red). The shaded region represents the 95% CI and points represent replicates from a single experiment. C) Dose-response curve for the transcriptional activity of the SARS-CoV-2 replication complex treated with high concentrations of TPGS, with 50% activity (blue, dashed line) and the critical micelle concentration of TPGS (red, dashed line) indicated. The upper limit of the model was not fixed. Points represent replicates from a single experiment. D) Doseresponse plot for increasing concentrations of αTOS (blue) and αTOP (red). Points represent replicates from a single experiment. E) Docking model of the most favorable pose for αTOS (white) interacting with conserved, hydrophobic residues (dark blue, named) within NSP7 (light blue). F) Docking model of the most favorable pose for αTOS (white) interacting with conserved, hydrophobic residues (dark green, named) within NSP8 (light green). G) Representation of the heterotetrameric structure of NSP7 (light blue) and NSP8 (light green) with the most favorable poses of αTOS interacting individually with each NSP7 (dark blue) and NSP 8 (dark green) superimposed. Figure S1 . Depiction of expedited generation of candidate drugs based on host-pathogen interactions/pathways and prioritized based on therapeutic potential and risk. A) Host and viral proteins essential for viral replication and genes related to patients' symptoms are input to mediKanren. B) Drugs with both direct and indirect impact on the protein's activity are returned. C) Candidates are selected and given higher priority based on their ability to decrease mechanisms favorable to viral replication or those resulting in COVID-19 symptoms (impacting multiple mechanisms is shown as multiple check marks). A lower priority is given to candidates that would activate mechanisms favorable to viral replication or thought to increase COVID-19 symptoms. Question marks indicate ambiguous or lack of results. Candidates that are predicted to primarily increase viral replication or COVID-19 symptoms are flagged for review by the clinical trial committee. These may be included in observational trials to guide best practices for treating COVID-19 patients. interacting with NSP12 (light red). B) Docking model of the ten most favorable poses for αTOS (white) interacting with conserved, hydrophobic residues (dark blue) within NSP7 (light blue). C) Docking model of the ten most favorable poses for αTOS (white) interacting with conserved, hydrophobic residues (dark green) within NSP7 (light green). D) Representation of the heterotetrameric structure of NSP7 and NSP8 with the most favorable poses of αTOS (opaque) interacting individually with each NSP7 (transparent, blue) and NSP 8 (transparent, green) superimposed. E) Table of the top ten poses for αTOS interacting with NSP7, NSP8, and NSP12. Values represent the predicted binding affinity in kcal / mol.